We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

60 hedge funds and large institutions have $92.6M invested in Invesco Biotechnology & Genome ETF in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

53% more capital invested

Capital invested by funds: $60.7M → $92.6M (+$31.9M)

18% more funds holding

Funds holding: 51 → 60 (+9)

4.78% more ownership

Funds ownership: 27.71% → 32.49% (+4.8%)

Holders
60
Holders Change
+9
Holders Change %
+17.65%
% of All Funds
1.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
21
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$9.3M
2
Bank of America
Bank of America
North Carolina
+$7.15M
3
U
UBS
Switzerland
+$5.32M
4
Wells Fargo
Wells Fargo
California
+$4.77M
5
AIG
American International Group
New York
+$691K

Top Sellers

Rank Fund Capital Flow
1
PFG
Pacific Financial Group
Washington
-$1.77M
2
VKH
Virtu KCG Holdings
New York
-$676K
3
CWM
Concert Wealth Management
California
-$661K
4
WBG
Wharton Business Group
Pennsylvania
-$293K
5
NCM
Niemann Capital Management
Nevada
-$239K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$293K +$284K +7,917 New
Janney Montgomery Scott
27
Janney Montgomery Scott
Pennsylvania
$278K +$6.63K +185 +3%
PFG
28
Pacific Financial Group
Washington
$274K -$1.77M -49,255 -87%
SB
29
Suntrust Banks
Georgia
$260K +$252K +7,022 New
Invesco
30
Invesco
Georgia
$259K – – –
PJSIMP
31
P.J. Schmidt Investment Management (PJS)
Wisconsin
$257K -$7.17K -200 -3%
CIC
32
Carnegie Investment Counsel
Ohio
$254K – – –
OC
33
Oppenheimer & Co
New York
$224K +$217K +6,047 New
B
34
Baird
Wisconsin
$210K +$203K +5,661 New
CAN
35
Cetera Advisor Networks
California
$201K -$11.9K -333 -6%
MAA
36
Managed Account Advisors
New Jersey
$180K +$15.9K +444 +10%
Ameriprise
37
Ameriprise
Minnesota
$152K +$122K +3,399 +486%
AP
38
Advisors Preferred
Maryland
$140K +$136K +3,801 New
Citigroup
39
Citigroup
New York
$124K +$40.7K +1,134 +51%
WEC
40
Winslow Evans & Crocker
Massachusetts
$120K +$116K +3,230 New
OIA
41
Optimum Investment Advisors
Illinois
$82K +$32.3K +900 +68%
1IC
42
1919 Investment Counsel
Maryland
$41K +$10.8K +300 +38%
PNC Financial Services Group
43
PNC Financial Services Group
Pennsylvania
$38K +$36.1K +1,006 New
Bank of Montreal
44
Bank of Montreal
Ontario, Canada
$37K – – –
BC
45
Bartlett & Co
Ohio
$37K – – –
LFR
46
Lehman Financial Resources
Pennsylvania
$22K – – –
RFA
47
Reilly Financial Advisors
California
$22K +$21.5K +600 New
Fifth Third Bancorp
48
Fifth Third Bancorp
Ohio
$19K – – –
NES
49
New England Securities
New York
$17K -$19.7K -550 -55%
MAS
50
Madden Advisory Services
Florida
$15K – – –
1
2
3

PBE Hedge Fund Activity: Q4 2013 in Review

60 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2013, worth a combined $92.6M — up 53% from $60.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PBE positions and 6 closed out — a net gain of 9 holders — while 21 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $9.3M. The largest seller was Pacific Financial Group, cutting an estimated $1.77M.

  • 60 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2013, up from 51 in Q3 2013.
  • Funds reported $92.6M of Invesco Biotechnology & Genome ETF stock for Q4 2013, up 53% quarter-over-quarter.
  • 15 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2013 and 6 closed out, a net change of +9 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q4 2013 was Morgan Stanley, an estimated $9.3M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q4 2013 was Pacific Financial Group, an estimated $1.77M sold.

Based on aggregated 13F filings for Q4 2013.